Opinion|Videos|April 29, 2025
Switching to Biosimilars for the Management of Psoriasis
Author(s)Aaron Farberg, MD
An expert discusses how examining biosimilars in trials ensures safety, efficacy, and interchangeability, key for clinical adoption. The phase 3 study’s week 52 results confirmed consistent pharmacokinetics, efficacy, and safety. As confidence grows, biosimilars will expand treatment access for psoriasis patients.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Why is it so critical to examine biosimilars in clinical trials?
- Discuss the importance of interchangeability and whether it is implemented in your clinical practice.
- What were the study methods for this interchangeability study?
- What were the key results seen in terms of pharmacokinetics, efficacy, and safety profile?
- How do you see the use of biosimilars evolving in the future for patients with psoriasis?
Advertisement
Related to this article
HYPERION trial data shows a 76% reduction in clinical worsening events among adults recently diagnosed with PAH.
Diabetes care improves when support adapts to real-life changes, removing barriers and sustaining daily habits beyond reminders, education, and one-time interventions.
Imlunestrant plus abemaciclib doubled median PFS in patients with ESR1-mutated advanced breast cancer.
Global Burden of Disease data show prevalence fell nearly 30% from 1990 to 2021, yet the number of women affected grew 9.1%.
Logistic regression beats machine learning to predict autoimmune hepatitis recurrence after liver transplantation.
A new blood test for adults as young as 40 years arrives as employers and insurers still treat Alzheimer disease as an old-age condition.
Itch and skin appearance outranked safety for 300 US adults with chronic hand eczema, but cancer risk came next.
Rebisufligene etisparvovec-hopf (Fayuvi; Ultragenyx) is a 1-time gene therapy that addresses the underlying cause of Sanfilippo syndrome type A.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves First Treatment for Sanfilippo Syndrome Type A
2
No Blood Biomarker Is Ready to Pick Psoriasis Therapy
3
Real-World Data: FACT vs Non-FACT CAR T Outcomes Compared
4
Oral GLP-1s, Medicare Bridge Reshape Obesity Care: Holly Lofton, MD
5